{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"APLS","limit":50},"count":50,"signals":[{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"y Offer Condition or the terms of the Offer in any manner adverse to holders of shares of Company Common Stock or that would, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect; or (G) impose any condition to the Offer other than the Offer Conditions. For the avoidance of doubt, the Purchaser shall not, without the prior written consent of the Company in its discretion, acc","filed_date":"2026-03-31","accession":"0001193125-26-134916","full_text":"https://origin.rootz.global/static/filing/0001193125-26-134916.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ed clinical trials for our product candidates, and preclinical studies, whether conducted by us or our current or any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and expectations regarding the anticipated results from these clinical trials or preclinical studies; our sales, marketing and distribution capabilities and strategi","filed_date":"2026-02-24","accession":"0001193125-26-065179","full_text":"https://origin.rootz.global/static/filing/0001193125-26-065179.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":44,"context":"could result in a default on our debt obligations. We have substantial accounts receivable, and any delays in collecting accounts receivable or the failure to collect accounts receivable could have a material adverse effect on our cash flows and results of operations. Our accounts receivable balance was $366.2 million as of December 31, 2025, which primarily consisted of EMPAVELI and SYFOVRE product sales receivable(s)","filed_date":"2026-02-24","accession":"0001193125-26-065179","full_text":"https://origin.rootz.global/static/filing/0001193125-26-065179.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":77,"context":"the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; 3. To hold an advisory vote on the compensation paid to our named executive officers;  4. To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers; and 5. Transaction of any other business that may properly come befo","filed_date":"2025-04-23","accession":"0000950170-25-056966","full_text":"https://origin.rootz.global/static/filing/0000950170-25-056966.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and expectations regarding the anticipated results from these trials; our sales, marketing and distribution capabilities and strategies, including for the commercial","filed_date":"2025-02-28","accession":"0000950170-25-029507","full_text":"https://origin.rootz.global/static/filing/0000950170-25-029507.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":47,"context":"could result in a default on our debt obligations. We have substantial accounts receivable, and any delays in collecting accounts receivable or the failure to collect accounts receivable could have a material adverse effect on our cash flows and results of operations. Our accounts receivable balance was $264.9 million as of December 31, 2024, which primarily consisted of EMPAVELI and SYFOVRE product sales receivable(s)","filed_date":"2025-02-28","accession":"0000950170-25-029507","full_text":"https://origin.rootz.global/static/filing/0000950170-25-029507.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":71,"context":"cated a willingness to continue to serve as director, if elected. If either Mr. Fonteyne or Ms. OBrien becomes unable or unwilling to serve, however, the proxies may be voted for substitute nominees selected by our board of directors. Class I Director Nominees  Biographical information as of March 31, 2024, including principal occupation and business experience during the last five years, for our nominees for election as Class I","filed_date":"2024-04-26","accession":"0000950170-24-049098","full_text":"https://origin.rootz.global/static/filing/0000950170-24-049098.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; our sales, marketing and distribution capabilities and strategies, including for the commercialization and manufact","filed_date":"2024-02-29","accession":"0000950170-24-023256","full_text":"https://origin.rootz.global/static/filing/0000950170-24-023256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"al amount of the Convertible Notes outstanding and held by third parties as of December 31, 2023. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things: increasing our vulnerability to adverse economic and industry conditions; limiting ou","filed_date":"2024-02-29","accession":"0000950170-24-023256","full_text":"https://origin.rootz.global/static/filing/0000950170-24-023256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; our sales, marketing and distribution capabilities and strategies, including for the commercialization and manufact","filed_date":"2024-02-27","accession":"0000950170-24-020614","full_text":"https://origin.rootz.global/static/filing/0000950170-24-020614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"al amount of the Convertible Notes outstanding and held by third parties as of December 31, 2023. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things: increasing our vulnerability to adverse economic and industry conditions; limiting ou","filed_date":"2024-02-27","accession":"0000950170-24-020614","full_text":"https://origin.rootz.global/static/filing/0000950170-24-020614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"s of each jurisdiction which requires such qualification, except where the failure to be so qualified or in good standing would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary","filed_date":"2023-11-01","accession":"0001193125-23-267745","full_text":"https://origin.rootz.global/static/filing/0001193125-23-267745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":74,"context":"dicated a willingness to continue to serve as director, if elected. If either Dr. Chan or Dr. Francois becomes unable or unwilling to serve, however, the proxies may be voted for substitute nominees selected by our board of directors. Class III Director Nominees  Biographical information as of March 31, 2023, including principal occupation and business experience during the last five years, for our nominees for election as Class","filed_date":"2023-04-21","accession":"0000950170-23-013761","full_text":"https://origin.rootz.global/static/filing/0000950170-23-013761.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":27,"context":"trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; &#x2022; our sales, marketing and distribution capabilities and strategies, including for the commercialization and","filed_date":"2023-02-21","accession":"0000950170-23-003438","full_text":"https://origin.rootz.global/static/filing/0000950170-23-003438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"th CAD. The primary and secondary therapies, which include corticosteroids, splenectomy, alkylating agents and immunosuppressive drugs, are associated with low response rates, relapses and clinically significant adverse effects. We believe that C3 inhibition has the potential to prevent C3-related opsonization and extravascular hemolysis in patients with CAD, and that inhibiting the complement system by targeting C3 may ha","filed_date":"2023-02-21","accession":"0000950170-23-003438","full_text":"https://origin.rootz.global/static/filing/0000950170-23-003438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"cused on the use of Beams proprietary base editing technology to discover new treatments for complement-driven diseases. | | |  |  | | |  |  |  Neurology R&D Highlights In April 2022 we completed enrollment for our ongoing and potentially registrational Phase 2 MERIDIAN study with systemic pegcetacoplan for amyotrophic lateral sclerosis.  We have begun IND-enabling studies for APL-1030, a first-in-cl","filed_date":"2022-04-20","accession":"0001193125-22-111096","full_text":"https://origin.rootz.global/static/filing/0001193125-22-111096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":69,"context":"cated a willingness to continue to serve as director, if elected. If either Mr. Dunlop or Mr. Machiels becomes unable or unwilling to serve, however, the proxies may be voted for substitute nominees selected by our board of directors.  8  [Table of Contents](#toc) **Class II Director Nominees** Biographical information as of March 31, 2022, including principal occupation and business experience during the last five years, for ou","filed_date":"2022-04-20","accession":"0001193125-22-111096","full_text":"https://origin.rootz.global/static/filing/0001193125-22-111096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"g and planned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ) or by any future collaborators, including the timing of dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials | | |  |  |  the ongoing commercialization of EMPAVELI and our preparation for the commercialization of intravitreal","filed_date":"2022-02-28","accession":"0001564590-22-007606","full_text":"https://origin.rootz.global/static/filing/0001564590-22-007606.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"icient to support approval in GA, we may be required to conduct an additional clinical trial, which would increase our costs and delay the program. Any such delay or other adverse impact could have a material adverse effect on our business. | | |  |  |  We will need substantial additional funding to allow us to support both the systemic and intravitreal pegcetacoplan programs through commercial launch, and, if we are un","filed_date":"2022-02-28","accession":"0001564590-22-007606","full_text":"https://origin.rootz.global/static/filing/0001564590-22-007606.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"s of each jurisdiction which requires such qualification, except where the failure to be so qualified or in good standing would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary","filed_date":"2022-01-20","accession":"0001193125-22-013866","full_text":"https://origin.rootz.global/static/filing/0001193125-22-013866.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"ned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials | | |  |  |  the ongoing commercialization of EMPAVELI and our preparation for the commercialization of intravitreal","filed_date":"2021-11-08","accession":"0001564590-21-055235","full_text":"https://origin.rootz.global/static/filing/0001564590-21-055235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"ficient to support approval in GA, we may be required to conduct an additional clinical trial, which would increase our costs and delay the program.Any such delay or other adverse impact could have a material adverse effect on our business. | | |  |  |  We will need substantial additional funding, to allow us to support systemic pegcetacoplan, intravitreal pegcetacoplan and any other product candidates through clinical","filed_date":"2021-11-08","accession":"0001564590-21-055235","full_text":"https://origin.rootz.global/static/filing/0001564590-21-055235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"ned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials | | |  |  |  the ongoing commercialization of EMPAVELI | | |  |  |  our sales, marketing and distribution capabiliti","filed_date":"2021-08-09","accession":"0001564590-21-042601","full_text":"https://origin.rootz.global/static/filing/0001564590-21-042601.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ge for approximately $201.1 million aggregate principal amount of Convertible Notes in July 2021. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things: |  |  |  increasing our vulnerability to adverse economic and industry conditions | |","filed_date":"2021-08-09","accession":"0001564590-21-042601","full_text":"https://origin.rootz.global/static/filing/0001564590-21-042601.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"ent of patients with PNH. SFJ paid the Company $60.0million following the signing of the agreement, and agreed to pay the Company up to an additional $60.0million in the aggregate in three equal installments upon the achievement of specified development milestones with respect to the Companys Phase 3 program for pegcetacoplan in PNH and subject to the Company having cash resources at the time suffici","filed_date":"2021-04-28","accession":"0001564590-21-021318","full_text":"https://origin.rootz.global/static/filing/0001564590-21-021318.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"mon stock in exchange for approximately $126.1 million of 2019 Convertible Notes in January 2021. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things: |  |  |  increasing our vulnerability to adverse economic and industry conditions | |","filed_date":"2021-04-28","accession":"0001564590-21-021318","full_text":"https://origin.rootz.global/static/filing/0001564590-21-021318.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"the committee  -26-  [Table of Contents](#toc) noted that our overall corporate performance, including the closing of the Sobi collaboration, the continued development of the PNH program and the enrollment of the DERBY and OAKS clinical trials, substantially exceeded expectations in 2020, particularly in light of COVID-19, and that we made significant progress on the corporate goals described above.","filed_date":"2021-04-22","accession":"0001193125-21-126688","full_text":"https://origin.rootz.global/static/filing/0001193125-21-126688.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":69,"context":"cated a willingness to continue to serve as director, if elected. If either Mr. Fonteyne or Ms. OBrien becomes unable or unwilling to serve, however, the proxies may be voted for substitute nominees selected by our board of directors.  **Class I Director Nominees** Biographical information as of March 31, 2021, including principal occupation and business experience during the last five years, for our nominees for election as Cla","filed_date":"2021-04-22","accession":"0001193125-21-126688","full_text":"https://origin.rootz.global/static/filing/0001193125-21-126688.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":31,"context":"g and planned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ) or by any future collaborators, including the timing of dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials |  | |  |  |  |  |  | |  |  |  |  our plans to develop our current and future product candidates for any additional","filed_date":"2021-02-25","accession":"0001564590-21-008800","full_text":"https://origin.rootz.global/static/filing/0001564590-21-008800.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"or CAD. The primary and secondary therapies, which include corticosteroids, splenectomy, alkylating agents and immunosuppressive drugs, are associated with low response rates, relapses and clinically significant adverse effects.  We believe that C3 inhibition has the potential to prevent C3-related opsonization and extravascular hemolysis in patients with CAD, and that inhibiting the complement system by targeting C3 may h","filed_date":"2021-02-25","accession":"0001564590-21-008800","full_text":"https://origin.rootz.global/static/filing/0001564590-21-008800.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"ursuant to the agreement, SFJ paid the Company $60.0million following the signing of the agreement, and agreed to pay the Company up to an additional $60.0million in the aggregate in three equal installments upon the achievement of specified development milestones with respect to the Companys Phase 3 program for pegcetacoplan in PNH and subject to the Company having cash resources at the time suffici","filed_date":"2020-11-02","accession":"0001564590-20-049423","full_text":"https://origin.rootz.global/static/filing/0001564590-20-049423.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"lt of the issuance of convertible notes in September 2019 and May 2020, or the Convertible Notes. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things: |  |  |  increasing our vulnerability to adverse economic and industry conditions | |","filed_date":"2020-11-02","accession":"0001564590-20-049423","full_text":"https://origin.rootz.global/static/filing/0001564590-20-049423.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"ursuant to the agreement, SFJ paid the Company $60.0million following the signing of the agreement, and agreed to pay the Company up to an additional $60.0million in the aggregate in three equal installments upon the achievement of specified development milestones with respect to the Companys Phase 3 program for pegcetacoplan in PNH and subject to the Company having cash resources at the time suffici","filed_date":"2020-07-30","accession":"0001564590-20-034763","full_text":"https://origin.rootz.global/static/filing/0001564590-20-034763.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"lt of the issuance of convertible notes in September 2019 and May 2020, or the Convertible Notes. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things: |  |  |  increasing our vulnerability to adverse economic and industry conditions | |","filed_date":"2020-07-30","accession":"0001564590-20-034763","full_text":"https://origin.rootz.global/static/filing/0001564590-20-034763.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"ursuant to the agreement, SFJ paid the Company $60.0million following the signing of the agreement, and agreed to pay the Company up to an additional $60.0million in the aggregate in three equal installments upon the achievement of specified development milestones with respect to the Companys Phase 3 program for pegcetacoplan in PNH and subject to the Company having cash resources at the time suffici","filed_date":"2020-04-29","accession":"0001564590-20-019689","full_text":"https://origin.rootz.global/static/filing/0001564590-20-019689.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"ess as a result of the sale of the convertible notes in September 2019, or the Convertible Notes. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things: |  |  |  increasing our vulnerability to adverse economic and industry conditions | |","filed_date":"2020-04-29","accession":"0001564590-20-019689","full_text":"https://origin.rootz.global/static/filing/0001564590-20-019689.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":59,"context":"dicated a willingness to continue to serve as director, if elected. If either Dr. Chan or Dr. Francois becomes unable or unwilling to serve, however, the proxies may be voted for substitute nominees selected by our board of directors.  **Class III Director Nominees** Biographical information as of March 31, 2020, including principal occupation and business experience during the last five years, for our nominees for election as C","filed_date":"2020-04-22","accession":"0001193125-20-115068","full_text":"https://origin.rootz.global/static/filing/0001193125-20-115068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":39,"context":"our plans with respect to our ongoing and planned clinical trials for our product candidates, whether conducted by us or by any future collaborators, including the timing of dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials |  | |  |  |  |  |  | |  |  |  |  our plans to initiate clinical trials of our current and future product candidates","filed_date":"2020-02-27","accession":"0001564590-20-007350","full_text":"https://origin.rootz.global/static/filing/0001564590-20-007350.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"or CAD. The primary and secondary therapies, which include corticosteroids, splenectomy, alkylating agents and immunosuppressive drugs, are associated with low response rates, relapses and clinically significant adverse effects.  We believe that C3 inhibition has the potential to prevent C3-related opsonization and extravascular hemolysis in patients with CAD, and that inhibiting the complement system by targeting C3 may h","filed_date":"2020-02-27","accession":"0001564590-20-007350","full_text":"https://origin.rootz.global/static/filing/0001564590-20-007350.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"the director is a member. The chair of each committee and the chair of the board of directors receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment is prorated for any portion of such quarter that the director is not serving on our board of directors, on such committee","filed_date":"2023-04-21","accession":"0000950170-23-013761","full_text":"https://origin.rootz.global/static/filing/0000950170-23-013761.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"pany. Typically, the stock options we grant to our executive officers have a ten-year term and vest as to 25% of the shares on the first anniversary of their grant date and then in equal monthly installments thereafter until the fourth anniversary of such date. Vesting of option grants to employees ceases upon termination of employment and exercise rights typically cease three months following termin","filed_date":"2020-04-22","accession":"0001193125-20-115068","full_text":"https://origin.rootz.global/static/filing/0001193125-20-115068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"the director is a member. The chair of each committee and the chair of the board of directors receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment is prorated for any portion of such quarter that the director is not serving on our board of directors, on such committee","filed_date":"2024-04-26","accession":"0000950170-24-049098","full_text":"https://origin.rootz.global/static/filing/0000950170-24-049098.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":78,"match_count":6,"context":"|  40,415 |  |  |  |  43,212 |  |  | |  Other |  |  |  30,821 |  |  |  |  16,171 |  |  | |  Total |  |  $ |  117,089 |  |  |  $ |  95,139 |  |  | On August 29, 2023, the Company announced a corporate restructuring plan to drive the growth of SYFOVRE and EMPAVELI and position the Company. As part of this plan, the Company reduced headcount by approximately 25% across the organization, and such reductions were substa","filed_date":"2023-11-01","accession":"0000950170-23-057117","full_text":"https://origin.rootz.global/static/filing/0000950170-23-057117.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; &#x2022; the ongoing commercialization of EMPAVELI and our preparation for the commercialization of intravitreal pe","filed_date":"2022-11-07","accession":"0000950170-22-022606","full_text":"https://origin.rootz.global/static/filing/0000950170-22-022606.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; &#x2022; the ongoing commercialization of EMPAVELI and our preparation for the commercialization of intravitreal pe","filed_date":"2022-08-08","accession":"0000950170-22-015500","full_text":"https://origin.rootz.global/static/filing/0000950170-22-015500.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ned clinical trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; &#x2022; the ongoing commercialization of EMPAVELI and our preparation for the commercialization of intravitreal pe","filed_date":"2022-05-04","accession":"0000950170-22-007374","full_text":"https://origin.rootz.global/static/filing/0000950170-22-007374.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"the director is a member. The chair of each committee and the chair of the board of directors receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment is prorated for any portion of such quarter that the director is not serving on our board of directors, on such committee","filed_date":"2025-04-23","accession":"0000950170-25-056966","full_text":"https://origin.rootz.global/static/filing/0000950170-25-056966.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":59,"match_count":3,"context":"affect the development of our product candidates. We have substantial accounts receivable, and any delays in collecting accounts receivable or the failure to collect accounts receivable could have a material adverse effect on our cash flows and results of operations. Our accounts receivable balance was $169.3 million as of September 30, 2023. While we monitor the financial performance and creditworthiness of our custom","filed_date":"2023-11-01","accession":"0000950170-23-057117","full_text":"https://origin.rootz.global/static/filing/0000950170-23-057117.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; &#x2022; our sales, marketing and distribution capabilities and strategies, including for the commercialization and","filed_date":"2023-11-01","accession":"0000950170-23-057117","full_text":"https://origin.rootz.global/static/filing/0000950170-23-057117.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APLS","company":"Apellis Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"trials for our product candidates, whether conducted by us or Swedish Orphan Biovitrum AB (Publ), or Sobi, or by any future collaborators, including the timing of initiation, dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; &#x2022; our sales, marketing and distribution capabilities and strategies, including for the commercialization and","filed_date":"2023-07-31","accession":"0000950170-23-035935","full_text":"https://origin.rootz.global/static/filing/0000950170-23-035935.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"6fd123737514cfbefdd769967b10aeee02c2702229a31905752863163978fd6f","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"2b8699a1f7f5481041128e7c5e7d2363081cf022e14e4ff19eedd3132c0640b8","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":5,"hourly_limit":500,"remaining":495,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}